Published Paper Details:

The present review article's main goal is to enlighten readers about Vildagliptin, a new oral anti-hyperglycemic drug that inhibits the dipeptidyl peptidase-4 inhibitor (DPP-4) and increases the release of insulin from Langerhans beta cells, lowering blood sugar levels. Vildagliptin is a medication with a short half-life (1.32-2.43 hours), making it a good candidate for the manufacture of sustained release tablets to extend the therapeutic effect. By applying the direct compression method and varying the ratios of polymers and excipients, sustained release tablets will be created. The mass, tapped, angle of repose, Carr's index, and Hausner's ratios of the powder will assess. The hardness, thickness, friability, weight fluctuation, drug content, and in vitro release of the produced tablets will assess. Utilizing 0.1N HCL as the dissolution medium, a dissolution research should be conducted using a USP type-II dissolution apparatus. The formulation's drug release methods include zero order, first order, the Higuchi model, and the Korsmeyer-Peppas model.